Bingwen Zou

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Radiation Induced

Dna Damage Response

Top Venues

Hepatology (Baltimore, Md.)

Future oncology (London, England)

Nanomedicine (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Qianqian Meng, Laraib Nadeem, Bingwen Zou
Letter to the Editor: The causal analysis of missing confounding factors for the association between HDV and specific liver events. Hepatology (Baltimore, Md.) (2024)
Yi Zhang, Zheng Li, Xi Chen, Ying Huang, Bingwen Zou, Yong Xu
Prognostic significance of FAT10 expression in malignant tumors: a systematic review and meta-analysis. Future oncology (London, England) (2024)
Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Jiayun Yu, Qianqian Meng, Bingwen Zou
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC. Hepatology (Baltimore, Md.) 79 (6) (2024)
Zheng Li, Yi Zhang, Ying Li, Xi Chen, Jie Hu, Jiayun Yu, Yuzhu Hu, Shihong Nie, Nanjing Li, Qinglian Wen, Bingwen Zou
Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC? Hepatology (Baltimore, Md.) 80 (3) (2024)
Zheng Li, Yi Zhang, Ying Li, Xi Chen, Jie Hu, Jiayun Yu, Yuzhu Hu, Shihong Nie, Nanjing Li, Qinglian Wen, Bingwen Zou
Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC? Hepatology (Baltimore, Md.) (2024)
Zheng Li, Yi Zhang, Ying Li, Xi Chen, Jie Hu, Jiayun Yu, Yuzhu Hu, Shihong Nie, Nanjing Li, Qinglian Wen, Bingwen Zou
Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC? Hepatology (Baltimore, Md.) 80 (3) (2024)
Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Jiayun Yu, Qianqian Meng, Bingwen Zou
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC. Hepatology (Baltimore, Md.) (2024)
Yi Zhang, Xi Chen, Binbin Hu, Bingwen Zou, Yong Xu
Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy. Nanomedicine (London, England) (2024)
Yi Zhang, Ying Huang, Zheng Li, Hanyou Wu, Bingwen Zou, Yong Xu
Exploring Natural Products as Radioprotective Agents for Cancer Therapy: Mechanisms, Challenges, and Opportunities. Cancers 15 (14) (2023)
Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, Meijuan Huang, Youling Gong, Bingwen Zou, Jiang Zhu, Yongmei Liu, Feng Peng, Yan Zhang, Min Yu, Yanying Li, Feifei Na, Yijun Wu, Kai Kang, Weigang Xiu, Xuanwei Zhang, Lin Zhou, Yong Xu, Jin Wang, Yan Wang, Xue Yang, Yuanjun Wu, Rui Li, Yu Zhang, Zhen Zhou Yang, Zhipeng Zhou, Jing Bai, Xin Yi, Ruizhan Tong, Limei Yin, Chong Chen, Gabriele Niedermann, You Lu, Jianxin Xue
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Na Xie, Lu Zhang, Wei Gao, Canhua Huang, Peter Ernst Huber, Xiaobo Zhou, Changlong Li, Guobo Shen, Bingwen Zou
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal transduction and targeted therapy 5 (1) (2020)
Bingwen Zou, Yan Tu, Duwen Liao, Yong Xu, Jin Wang, Meijuan Huang, Li Ren, Jiang Zhu, Youling Gong, Yongmei Liu, Lin Zhou, Xiaojuan Zhou, Feng Peng, You Lu
Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial? Thoracic cancer 11 (3) (2020)